NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is projected to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.01 on Thursday. The stock has a market capitalization of $34.00 million, a PE ratio of -0.94 and a beta of 1.22. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The company has a 50 day moving average price of $2.47 and a 200-day moving average price of $2.05.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NRXP shares. BTIG Research began coverage on NRx Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $18.00 target price on the stock. D. Boral Capital restated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, March 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $28.25.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.